Skip to main content
Article thumbnail
Location of Repository

Antibiotic Innovation May Contribute to Slowing the Dissemination of Multiresistant Streptococcus pneumoniae: The Example of Ketolides

By Lulla Opatowski, Laura Temime, Emmanuelle Varon, Roland Leclerc, Henri Drugeon, Pierre-Yves Boëlle and Didier Guillemot
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2330086
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). The state of antibiotic resistance surveillance: an overview of existing activities and new strategies.
    2. (1997). Antibiotic resistance in Streptococcus pneumoniae.
    3. (2004). Antibacterial resistance worldwide: causes, challenges and responses.
    4. (2000). Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance,
    5. (1996). Carriage of pneumococci after pneumococcal vaccination.
    6. (2006). European Antimicrobial Resistance Surveillance System (EARSS)
    7. (2001). Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance.
    8. (2003). Decline in invasive pneumococcal disease after the introduction of protein– polysaccharide conjugate vaccine.
    9. (2006). Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
    10. (2007). Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.
    11. (2007). Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae.
    12. (2007). de la Statistique et des Etudes Economiques (INSEE)
    13. (2004). Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings.
    14. (1975). Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types.
    15. (1997). Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project.
    16. (2004). Estimating the transmission parameters of pneumococcal carriage in households.
    17. (2006). S. pneumoniae transmission according to inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools.
    18. (2007). Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci.
    19. (2002). Advice of the French Superior Council on Public Health (section on transmissible diseases) relative to vaccination by heptavalent pneumococcal conjugate vaccine (Prevenar). Meeting of
    20. (2004). Disease Control and Prevention (CDC)
    21. (2006). Veille Sanitaire (InVS)
    22. (2004). Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance.
    23. (2006). Pneumococcal resistance in the postvaccine era.
    24. Health Insurance. French Surveillance of Antimicrobial Consumption Program,
    25. (1999). beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins.
    26. (2005). Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides.
    27. (2002). Will resistance to ketolides develop in Streptococcus pneumoniae?
    28. (2005). Telithromycin-resistant Streptococcus pneumoniae.
    29. (2005). Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.
    30. (2001). Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin.
    31. (2004). No significant decrease in antibiotic use from 1992 to 2000, in the French community.
    32. (2005). Centre National de Re ´fe ´rence des Pneumocoques. Rapport d’activite ´ 2005: Epide ´miologie
    33. (2004). Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ile de France area.
    34. (2007). Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years
    35. (1994). Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV Model, as an example.
    36. (1999). Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae.
    37. (2001). Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae.
    38. (2003). Bacterial resistance to penicillin G by decreased affinity of penicillin-binding proteins: a mathematical model.
    39. (2005). Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.
    40. (2006). Antibody-independent, interleukin-17A–mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide.
    41. (2006). The biological cost of mutational antibiotic resistance: any practical conclusions?
    42. (2006). Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model.
    43. (2007). Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
    44. (2007). Food and Drug Administration (FDA)
    45. (2007). The FDA and the case of Ketek.
    46. (2007). Ketek–the FDA perspective.
    47. (2004). Consequences of bacterial resistance to antimicrobial agents. Emerg Infect Dis 10: 759–760. Modeling New Drug’s Impact PLoS
    48. (2001). Economic impact of antimicrobial resistance.
    49. (2006). Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.
    50. (2004). Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.
    51. (2006). Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.